We analysed the subcellular distribution of p210 BCR-ABL protein using a junction-specific anti-BCR-ABL monoclonal antibody and confocal laser scanning microscopy (CLSM). Our studies have shown that p210 BCR-ABL is arranged in discrete foci in the cytoplasm of cell lines and primary CD34 þ cells but not mononuclear cells suggesting the foci may be a feature of immature chronic myeloid leukaemia cells. We have devised a strategy to score the foci and found the mean number of foci varies between the cell types. The number of foci per cell is directly related to the level of p210 BCR-ABL expression. CLSM was also used to analyse the distribution and colocalization of CT10 regulator-like (CRKL) p210
Introduction

p210
BCR-ABL has a central role in chronic myeloid leukaemia (CML). This fusion protein arises due to a translocation that brings the Abelson murine leukaemia virus (ABL) and breakpoint cluster region (BCR) genes into juxtaposition to form the characteristic Philadelphia (Ph) chromosome. First described by Nowell and Hungerford in 1960, 1 the chimeric protein product p210
BCR-ABL has constitutively activated tyrosine kinase activity 2 resulting in unregulated expansion of the myeloid series.
The p210 BCR-ABL fusion protein forms intracellular complexes with multiple protein partners in cell lines, as demonstrated by immunoprecipitation (IP) and western blotting. [3] [4] [5] [6] [7] [8] These observations have evoked a model in which p210
BCR-ABL recruits signalling enzymes and adaptor molecules into multimolecular complexes and activates them. 9 Until recently, few studies had investigated these complexes in primary CML cells 10, 11 because it was difficult to carry out IP and western blotting studies of ABL proteins in primary cells. These cells contain a proteolytic activity that rapidly and selectively degrades p145 ABL and p210 BCR-ABL when the cells are lysed in a conventional manner. Recently, we developed a method for inhibiting the proteolytic degradation by high-pH lysis that maintains protein integrity and allows IP studies of p145 ABL and p210 BCR-ABL in primary cells for the first time. 12 CT10 regulator like (CRKL) protein was first cloned by ten Hoeve in 1993 13 on chromosome 22. The gene encodes for a 39 kDa protein that is found most abundantly in haemopoietic tissue.
14 Ph À cell lines and primary cells 4, [15] [16] [17] [18] lack phosphorylated CRKL (pCRKL) but do express CRKL protein. CRKL complexes with p210 BCR-ABL in Ph þ cell lines 18 and we have shown CRKL and p210
BCR-ABL complex in primary CD34 þ cells by co-IP using the high-pH lysis assay. 12 Levels of CRKL phosphorylation can be used as an indirect marker of p210 BCR-ABL function in response to therapy by western blot 19 and fluorescence-activated cell sorting assay. 20 Many questions remain about the composition of the protein complexes in primary CML cells. In particular, it is not known if the complexes incorporate all of the implicated proteins all of the time, if their composition can be modified or what implications changes may have on intracellular signalling or cell function. Confocal laser scanning microscopy (CLSM) can be used to analyse colocalized proteins in single cells 21 but studies of proteins colocalized with p210 BCR-ABL have been confounded by the lack of an antibody that specifically recognizes the fusion proteins. Instead, antibodies to ABL or BCR have been used although these detect the normal cellular proteins as well. Studies were conducted by Wetzler et al. 22 and Skourides et al. 8 which demonstrated that the p210 BCR-ABL /ABL protein is distributed in punctuate structures in the cytoplasm. The study by Wetzler et al. 22 analysed the differences between the subcellular distribution of p210 BCR-ABL , normal ABL and normal BCR in various cell lines, and Skourides et al. 8 demonstrated a similar cytoplasmic distribution of p210 BCR-ABL / ABL in transfected haemopoietic and fibroblast cells. They further showed that p210 BCR-ABL /ABL and adaptor proteins such as growth factor-binding protein (GRB2), src homologous and collagen gene and casitas B-cell lymphoma (CBL) colocalize with p210 BCR-ABL in transfected fibroblast cells. The recent availability of a p210 BCR-ABL antibody that recognizes the b2a2 junction sequence (Cell Signalling Technologies, MA, USA) means that the specific distribution of p210 BCR-ABL can be visualized. Here, we used this antibody to show that p210 BCR-ABL protein forms distinct foci in the cell cytoplasm that are variously associated with CRKL. We also show that imatinib, a small molecule tyrosine kinase inhibitor, changes the subcellular distribution of the p210 BCR-ABL and prevents it from forming complexes with some partner proteins, confirming previous observations that imatinib treatment causes nuclear transport of p210 BCR-ABL in CML cells lines. 23, 24 Our study provides a detailed description of p210 BCR-ABL distribution in primary CML patient cells at different maturation levels and in various CML cell lines. We describe detailed approaches to determine and quantify the subcellular distribution and protein-protein interactions in single CML cells.
Materials and methods
Cells for study
CML cell lines KCL-22 (myeloid), KYO-1 (myeloid) (kindly provided by Professor Junia Melo, Imperial College, Faculty of Medicine, UK), BV173 (lymphoid) and K562 (myeloid) were grown in the laboratory in RPMI-1640 medium (Gibco, Paisley, UK) supplemented with 10% fetal calf serum (FCS) (BioSera, East Sussex, UK) and 1% penicillin and streptomycin (Gibco). Haemopoietic cells from newly diagnosed CML patients with known b2a2 junctions were obtained from excess material from leukapheresis taken for clinical purposes. All patients and donors gave informed consent in accordance with local ethics committee guidelines.
Cell separation
Mononuclear cells (MNCs) were separated from leukapheresis samples by density gradient centrifugation (Lymphoprep, AxisShield, Oslo, Norway), harvested from the interface and washed three times in Hanks' balanced salt solution (Gibco). CD34 þ cells were purified from MNC using MiniMACS immunomagnetic bead technology following the manufacturer's recommendations (Miltenyi Biotec Ltd, Bergisch Gladbach, Germany).
Cell treatment
BV173 and CD34 þ CML cells were incubated with 1 mM imatinib (kindly provided by Prof. Junia Melo, Imperial College, Faculty of Medicine, UK) in Alpha MEM medium (Gibco) supplemented with 15% FCS for up to 16 h. Treated and untreated cells were used for immunofluorescence and western blot.
Immunofluorescence
CML cell lines, primary CML MNCs and CML CD34
þ cells were re-suspended in Alpha MEM medium (Gibco) at 10 6 cells per ml and 30 ml aliquots were air-dried on to glass microscope slides (VWR, Leicestershire, UK) and fixed in 2% paraformaldehyde (PFA) in phosphate-buffered saline (PBS) for 10 min at room temperature. For intracellular staining cells were permeabilized using 0.2% Triton X-100 (Sigma, Poole, UK) in PBS for 10 min at room temperature. Non-specific sites were blocked using 5% fetal bovine serum (FBS) (Biosers, Ringmer, UK)/3% bovine serum albumin (BSA; PAA laboratories, Linz, Austria) in PBS (blocking solution) for 1 h. p210
BCR-ABL was labelled using 0.5 mg ml À1 mouse anti-BCR-ABL (b2a2 junction-specific) antibody (Catalogue number L99H4, Cell Signalling Technology), anti-ABL (Santa Cruz Biotechnology, Wiltshire, UK) or mouse immunoglobulin G (IgG) 2a isotype-negative control (BD Biosciences Pharmingen, Oxford, UK) in blocking solution for 1 h. After four 5 min washes in 3% FBS/1% BSA in PBS (wash solution), cells were incubated with 1 mg ml À1 donkey antimouse Alexa Fluor 488 in blocking solution for 1 h in the dark. Four 5 min washes in wash solution were repeated and slides were mounted in VECTASHIELD containing 4,6-diamidino-2-phenylindole (DAPI; Vector Laboratories, Burlingame, CA, USA).
For dual staining cells were treated as previously described except both primary and secondary antibodies were incubated together. Additional antibodies used were 0.5 mg ml À1 anti-GRB2, anti-CRKL and anti-CBL (all from Autogen Bioclear, Calne, UK). 
Strategy for scoring p210
BCR-ABL -positive foci
To quantify the number of p210 BCR-ABL -positive foci we devised the scoring system depicted in Figures 1a and b . After acquiring the Z scan images of CML cells using confocal microscopy the distinct p210 BCR-ABL foci in each section were scored. Any diffuse green signal on the images was considered as background staining and not included in the count. We define a focus by the following criteria:
(1) high intensity of staining around a point represents a focus. Scoring from the Z scans eliminates the possibility of counting any of the foci more than once.
Strategy of scoring percentage of p210
BCR-ABL in foci
The percentage of p210 BCR-ABL in the foci was scored using ImageJ. 25 Confocal images were uploaded into ImageJ and the integrated density (ID) was measured for the whole cell followed by the ID for single foci. The percentages of p210 BCR-ABL in the foci and diffused p210 BCR-ABL were calculated using the following formulae:
Measurement of the colocalization coefficient
Colocalization analysis was performed on randomly selected cells (n420) using Zeiss LSM 510 meta software. The colocalization coefficient, defined by Manders et al. 26 is calculated where 1 indicates complete colocalization while 0 indicates no colocalization. The intensity of the pixels does not affect the calculation as the pixel intensity in a certain channel is normalized by the total number of pixels and pixels with zero intensity are considered as background. Briefly, the region of interest (ROI) is selected (Figure 2a ), which generates a scatter diagram of the number of red pixels against the number of green pixels ( Figure 2b ). To accurately determine the proportion of yellow signal a threshold, which is automatically calculated by the software at the mean fluorescence intensity (MFI) of ROI þ 2 standard deviations ( Figure 2c ). The software generates the colocalization coefficient (proportion of protein complexed) for each signal (Figure 2d ).
Western blotting
Preparation of cell lysate: cells were washed twice in Ca 2 þ / Mg þ þ -free PBS. The cell pellet was manually dispersed and then vigorously re-suspended in 200 ml ice-cold lysis buffer (1% Triton X-100 (Sigma), 150 mM NaCl, 1 mM MgCl 2 , 10% glycerol (Invitrogen, Paisley, UK), 20 mM Tris (pH 8) and a proprietary protease inhibitor cocktail (Complete tablets, Roche, Mannheim, Germany), per 10 7 cells. The lysate was incubated on ice for 10 min, and then the cells were sheared by rapid expulsion through a 21-gauge needle. The crude lysate was centrifuged at 4 1C for 3 min at 13 000 r.p.m. For western blotting, the lysates were mixed with an equal volume of loading buffer (2.3% sodium dodecyl sulphate (SDS), 10 mM DL-DTT (DTT), 0.01% bromophenol blue (all Sigma, Paisley, UK), 10% glycerol, and 62.5 mM Tris (pH 6.8) and boiled for 5 min at 100 1C and Kaleidoscope prestained molecular weight markers (Bio-Rad, Hemel Hempstead, UK) were run in parallel on 6 and 10% SDSpolyacrylamide gel electrophoresis minigels (37.5:1 acrylamide:bisacrylamide; Bio-Rad) at 100 V and transferred to 0.45 mm polyvinylidenedifluoride membranes (Immobilon, Sigma) by a semi-dry transfer system (Bio-Rad). Membranes were blocked with 1% milk (Marvel milk powder, Nestle, Croydon, UK) in Tris-buffered saline (TBS)-Tween and anti-BCR-ABL (junctionspecific) antibody (1:1000), anti-ABL or anti-actin were incubated overnight at 4 1C. Membranes were washed four times in TBS-Tween for 5 min, stained for 30 min at room temperature with appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies diluted at 1:1000 in 1% milk, washed four times in TBS-Tween for 5 min and visualized by chemiluminescence (ECL, Amersham Biosciences, Piscataway, NJ, USA) on Kodak Biomax MR film (Sigma).
Immunoprecipitation
ExactaCruz (Santa Cruz Biotechnology) was also used to immunoprecipitate p210 BCR-ABL from imatinib-treated K562 cells. The ExactaCruz matrix was prepared as per the manufacturer's protocol. In brief, for 10 7 cells lysed in 200 ml lysis buffer (as described for western blot protocol), antibodymatrix complex was formed by incubating 100 ml of IP matrix and 10 mg ml À1 anti-c-ABL or mouse IgG in 500 ml of Ca 2 þ / Mg þ þ -free PBS for 2 h at 4 1C. The matrix was washed twice with cold Ca 2 þ /Mg þ þ -free PBS and then incubated with cell lysate for 1 h at 4 1C. After two washes in 500 ml cold Ca 2 þ /Mg þ þ -free PBS, the matrix was suspended in 80 ml of loading buffer and boiled for 5 min and then western blotted to detect protein complexes.
Statistical analysis
Statistical significance of unpaired data was analysed by the Mann-Whitney U-test and paired data were analysed by the Wilcoxon test using SSPS 14.0 (Chicago, IL, USA, 2005). A value Po0.05 was considered significant. Correlation (r) was estimated by Pearson's correlation coefficient.
Results
Specificity of the junction-specific BCR-ABL antibody
The BV173 cell line expresses p210 BCR-ABL with the b2a2 (e13/a2) breakpoint while K562 cells express p210 BCR-ABL with the b3a2 (e14/a2) breakpoint. We have used these cell lines to confirm the specificity of the junction-specific BCR-ABL antibody by western blotting and immunofluorescence ( Figure 3) . The results show that p210 BCR-ABL and p145 ABL proteins were detected in both cell lines by the anti c-ABL antibody and anti-BCR antibodies but only p210 BCR-ABL is detected in BV173 cells by the anti-BCR-ABL antibody, using western blotting (Figure 3a ) and immunofluorescence microscopy ( Figure 3b ).
Subcellular distribution of p210 BCR-ABL in CML cells
The results in Figure 3b suggested a degree of subcellular localization of p210 BCR-ABL since areas of high-intensity staining were visible in the BV173 cells. To investigate this pattern further we used CLSM on the BV173, KCL-22 and KYO-1 cell lines, all of which express p210 BCR-ABL with the b2a2 breakpoint. The results in Figures 4a, b and c clearly show that a multifocal distribution of p210 BCR-ABL could be discerned in all three cell lines, myeloid as well as lymphoid. Next we investigated the distribution of p210 BCR-ABL in primary CD34 þ and mononuclear CML cells. Three independent CML samples (CML 1, CML 2 and CML 3) were analysed. The CD34 þ cells exhibited clear foci (Figure 5a ), like the cell lines, but more diffuse staining characterized the MNCs (Figure 5b ). This observation indicates that the distribution of p210 BCR-ABL may be related to cellular maturation.
Quantification of p210 BCR-ABL in CML cell lines and primary cells
To quantify the observed differences in the number of foci per cells observed in cell lines and primary CD34 þ CML cells we used the scoring system described in 'Materials and methods' (Figure 1) . Altogether 100 cells of each cell line and 100 primary CD34 þ cells per patient (n ¼ 3) were scored in this manner. Figure 6a shows the number of foci per cell in the CML cell lines (KCL-22, KYO-1, BV173) and in three primary CD34 þ CML samples (CML 1, CML 2 and CML 3) and Figure 6b shows the mean number of foci and total levels of p210 BCR-ABL per cell. There is a statistically significant difference between the number of foci per cell in cell lines and primary CD34 þ cells (Po0.001; Figure 6c ). The variation between CML patient samples is smaller but analysis shows that the differences within this group are still statistically different (Po0.005, Po0.001) suggesting the focal distribution among CML samples is heterogeneous. We measured the total amount of p210 BCR-ABL expressed in each of the cell types by ImageJ analysis (Figure 6b ). There is a statistically significant correlation between total levels of p210 BCR-ABL and the number of foci per cell in the CML cell lines and patient samples (r ¼ 0.989, Po0.0001). This implies that the variation in the number of foci per cell type is directly related to differences in the total levels of p210 BCR-ABL (Figure 6b ). p210
BCR-ABL focal distribution is similar between BV173 and KYO-1 cells but KCL-22 cells express many more foci relative to all the cell types we have tested (Po0.001). Using ImageJ 25 to measure the ID of the whole cell and for all foci stained with p210
BCR-ABL , we show that the greater part of p210 BCR-ABL for all the cell types is diffused rather than in the foci (Figure 7a ). Using the same method we scored the levels of p210 BCR-ABL in the MNC and CD34 þ cell fractions of the three CML patients analysed in Figure 5 . We found that levels of p210 BCR-ABL in the CD34 þ cell fraction were 50.37% on average higher than levels in the MNC fraction (n ¼ 3). Since focus formation is directly related to the p210 BCR-ABL expression levels and the levels are lowest in MNC, it appears that focus formation requires a threshold amount of protein in the cell. 
Association of CRKL with p210 BCR-ABL in CML cells
To confirm the utility of CLSM as a method for investigating protein complexes in CML cells we analysed the association of CRKL with p210 BCR-ABL . This revealed that CRKL, as well as p210 BCR-ABL , formed distinct foci in the cytoplasm of the CD34 þ CML cells (Figure 8a ). Using the colocalization analysis software we quantified the proportion p210 BCR-ABL complexed with CRKL in BV173 cells (Figure 8a) . From 31 cells analysed we found that 20.08% (±0.35) of total CRKL is complexed with 43.93% ( ± 0.65) p210 BCR-ABL . Therefore, the distributions of CRKL and p210 BCR-ABL were not identical. Rather, foci of CRKL could be coincident, overlapping, touching or separate (Figure 8b ). This distribution of p210 BCR-ABL and CRKL foci suggests that the association of these proteins may be in a state of dynamic equilibrium. Since it is well established that CRKL is highly phosphorylated in CML and binds to p210 BCR-ABL , we next analysed the association between pCRKL and p210 BCR-ABL in BV173 cells with CLSM (Figure 9a) . Unexpectedly, we found only a small proportion, 14.01% ( ± 0.25) of pCRKL in complex with 31.32% (±0.69) of p210 BCR-ABL (Figure 9b ). Colocalization was concentrated in the foci with very minor complexing in the diffusely staining regions. Since 44% of p210 BCR-ABL colocalizes with total CRKL, 56% does not and 86% of pCRKL is not complexed with p210 BCR-ABL , this result indicates various possible mechanisms: (1) that CRKL could possibly bind to p210 BCR-ABL irrespective of its phosphorylation status and/or (2) CRKL phosphorylation is not dependent on p210
BCR-ABL and CRKL complex formation and/or (3) p210 BCR-ABL does not phosphorylate all of the cellular CRKL.
The colocalization analysis has also shown that large proportions of CRKL (Figure 8 ), pCRKL ( Figure 9 ) and p210 BCR-ABL remain uncomplexed. To test if this is unique to unphosphorylated and phosphorylated CRKL or common to other p210
BCR-ABL binding partners we analysed the cellular distribution of GRB2 and CBL with p210 BCR-ABL and CRKL. We found that 21.12% ( ± 0. CBL (Figure 10d ) colocalized. These data imply that low levels of p210 BCR-ABL are found in complex with CBL, and GRB2 and the proportion of CRKL in complex with these proteins is greater than the amount of CRKL complexed with p210 BCR-ABL .
Imatinib treatment on p210 BCR-ABL -positive foci and associated protein complexes
When we treated BV173 and CD34 þ CML cells with 1 mM imatinib for 16 h the p210 BCR-ABL -positive foci translocated to the nucleus since they colocalized with the nucleus, stained with DAPI. This translocation was more prominent in BV173 cell lines compared with primary CD34 þ CML cells (Figure 11 ). Using the ImageJ software we analysed the density of the p210 BCR-ABL signal that is present in the area stained with DAPI. This analysis indicated that p210 BCR-ABL located in the DAPI-stained regions of treated cells was 2-and 2.5-fold higher relative to untreated cells in BV173 and CD34
þ CML cells, respectively. Moreover, our IP and western blot analysis on K562 cells treated with imatinib has shown that the p210 BCR-ABL -CBL and p210
BCR-ABL -CRKL complexes dissociate but the p210 BCR-ABL -GRB2 complex remains intact even after 24 h of imatinib treatment (unpublished data). . The focal arrangement of p210 BCR-ABL reported here implies a higher order of organization than simply random distribution in the cytosol. Since proteins generally interact with other proteins to perform essential roles in important cellular functions, 27 it is likely that different arrangements of p210 BCR-ABL will have an impact on downstream signalling events and degrees of dysregulation of signalling pathways such as PI3 kinase, RAS and JAK-STAT linked to CML pathology.
We used the junction-specific anti-BCR-ABL antibody that recognizes the b2a2 (e13a2) breakpoint of p210 BCR-ABL to detect p210 BCR-ABL by CSLM. The b2a2 and b3a2 (e14a2) are the two major breakpoints in CML 28 and there is literature which suggests that expression of certain breakpoints has varied prognosis 29, 30 and duration of chronic phase (reviewed by Mills et al. 31 while other published data found no significance between breakpoint expression and prognosis 32 ). We cannot contribute to this controversy until a b3a2-specfic antibody is available. Previously, others have shown that p210 BCR-ABL forms punctuate focus-like structures in the cytoplasm of p210 BCR-ABL -positive cells. 8, 22 Our data show a similar distribution of p210 BCR-ABL but the advantage of our study is that we detect p210 BCR-ABL exclusively without detecting normal ABL or BCR. We also describe detailed approaches to quantify levels of p210 BCR-ABL and complexing partner proteins in different cell types and primary CML cells at different levels of maturation. We show p210 BCR-ABL is expressed as foci in the cell lines tested, both myeloid and lymphoid, and in primary CD34
þ CML cells. However, greater numbers of foci were scored in cell lines, particularly in the KCL-22 cells, than in primary CD34 þ cells. In contrast a diffuse distribution characterized MNC populations (Figures 3, 4 , 6 and 7) and this correlates with the cellular levels of p210 BCR-ABL . There has been recent interest in cell maturation-related differences of p210 BCR-ABL expression in primary CML cells because they are thought to be related to the relative imatinib resistance of primitive progenitor cells in CML. Evidence suggests that more primitive CML cells express higher levels of p210 BCR-ABL and that levels decrease with cellular maturation. 33 The CLSM comparison of primary CD34 þ and mononuclear CML cell populations revealed a further difference that is likely to be related to cellular maturation. Thus, p210
BCR-ABL is distributed in foci in CD34 þ cells but is diffusely distributed in MNCs. We show that CML CD34 þ cells have 41.96-46.18% higher levels of p210 BCR-ABL relative to MNC cells from the same CML patients (Figure 7b ). This difference between MNC and CD34 þ cells confirms that focus formation is not a technical artefact. However, to further confirm that the staining is not an artefact of the protocol we used the same method to stain and analyse F-actin distribution, which is diffuse (data not shown). Moreover, Deng et al. 34 report that fixation tends to result in dispersion of foci of MLL-5 protein. One interesting speculation is that focus formation by p210 BCR-ABL renders it less accessible to the actions of imatinib than a diffuse distribution. Alternatively, complexed p210 BCR-ABL may be more stable than diffuse p210 BCR-ABL by association with SHP-2 phosphatase. 35 Our preliminary observation suggests that p210 BCR-ABL and SHP-2 may associate within the foci in CD34
þ CML cells (unpublished data).
The association of CRKL with p210 BCR-ABL and CRKL phosphorylation in CML has received considerable attention recently due to its value in monitoring clinical responsiveness and resistance to the p210 BCR-ABL protein tyrosine kinase inhibitor, imatinib. 19, 20 In this regard, it has been shown that normal cells contain little pCRKL whereas CRKL is predominantly phosphorylated in CML. The mechanism of CRKL phosphorylation is not certain but it is known that the SH3 domain on CRKL binds to the proline-rich region on p210 36 and the tyrosine 207 residue on the SH3 domain is essential for CRKL phosphorylation in p210 BCR-ABL -positive cells. 36 CLSM has revealed that only a small portion of CRKL and p210 BCR-ABL foci colocalize completely while other foci partially overlap, touch or are separate. This unexpected distribution of p210 BCR-ABL and CRKL suggests that the association between the proteins is in a state of dynamic equilibrium (Figure 8 ), which may presumably be determined by the dissociation constant of proteins in the complex for one another and possibly by competition of p210 BCR-ABL binding proteins. We have also shown that the percentage colocalization of pCRKL and p210 BCR-ABL is low ( Figure 9 ) which implies various potential mechanisms of CRKL phosphorylation in CML: (1) Alternatively, GRB2 may bind to ABL in a similar way as CRKL and CBL. 45 Figure 10 for example do they act as site for assembly of signalling proteins that would support our dynamic equilibrium hypothesis? Does the p210 BCR-ABL in the diffuse region also have an important role in signal transduction in CML?
Deregulated tyrosine kinase is a major feature of CML and this can be inhibited by the use of imatinib that has improved CML treatment significantly. Imatinib, a 2-phenylaminopyrimidine derivative is a small molecule tyrosine kinase inhibitor which targets p210
BCR-ABL , ABL, c-Kit and platelet-derived growth factor receptor. [46] [47] [48] Our data imply that treating cells with imatinib promotes nuclear localization of p210 BCR-ABL -positive foci in BV173 and CD34 þ cells ( Figure 11 ) and confirm previous reports. 23 We have also shown that imatinib dissociates certain p210 BCR-ABL -associated protein complexes (unpublished data). Nishihara et al. 49 showed that there is a change in levels of phosphorylated p210 BCR-ABL , CBL and CRKL within minutes of treatment with 30 mM imatinib in the TF-1 BCR-ABL cell line. They also demonstrated by co-IP that p210 BCR-ABL complexed to CRKL and CBL and CBL bound to CRKL in these cells was reduced within 30 min or less post-treatment with 30 mM imatinib but total protein levels of p210 BCR-ABL , CRKL and CBL remain unchanged.
In summary, we believe that our work raises some important questions about the biology and localization of p210
The results support the use of CLSM as an alternative approach to the investigation of multimolecular protein complexes in CML and how their composition may change with disease stage, cellular maturation and exposure to therapeutic agents like imatinib and new generation tyrosine kinase inhibitors.
